Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder

Journal of Clinical Psychopharmacology

Volumn 19, Issue 4, 1999, Pages 329-335

  Fava, Maurizio ^a   Rosenbaum, Jerrold F ^a   Kolsky, Andrea R ^a   Alpert, Jonathan E ^a   Nierenberg, Andrew A ^a   Spillmann, Maya ^a   Moore, Constance ^b   Renshaw, Perry ^b   Bottiglieri, Teodoro ^c   Moroz, Georges ^d,e   Magni, Guido ^d,e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MCLEAN HOSPITAL   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d HOFFMANN LA ROCHE INC   (United States)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINE; INOSITOL; S ADENOSYLMETHIONINE; TOLCAPONE;

ADULT; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; FEMALE; FRONTAL LOBE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HUMAN; LIVER FUNCTION TEST; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

ADULT; BENZOPHENONES; CATECHOL O-METHYLTRANSFERASE; CAUDATE NUCLEUS; CHOLINE; DEPRESSIVE DISORDER, MAJOR; FEMALE; FRONTAL LOBE; HUMANS; INOSITOL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NITROPHENOLS; PERSONALITY INVENTORY; REFERENCE VALUES; S-ADENOSYLMETHIONINE; TREATMENT OUTCOME;

EID: 0032808536     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199908000-00008     Document Type: Article

References (21)

1. Zurcher G, Dingemanse J, Da Prada M. Potent COMT inhibition by Ro-40-7592 in the periphery and in the brain. Adv Neurol 1993;60:641-7.
2. Borgulya J, Bruderer H, Bernauer K, Zurcher G, Da Prada M. Catechol-O-methyl-transferase-inhibiting pyrocatechol derivatives: synthesis and structure-activity studies. Helv Chim Acta 1989; 72:952-68.
3. Da Prada M, Zurcher G, Kettler R, Colzi A. New therapeutic strategies in Parkinson's disease: inhibition of MAO-B by Ro 19-6327 and of COMT by Ro 40-7592. Adv Behav Biol 1991;39:723-32.
4. Limousin P, Polk P, Gervason-Tournier C-L, Hommel M, Perret JE. Ro 40-7592, a COMT inhibitor, plus levodopa in Parkinson's disease [letter]. Lancet 1993;341:1605.
5. Kurth MC, Adler CH, Hilaire MS, Singer C, Waters C, LeWitt P, Chernik DA, Dorflinger EE, Yoo K. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology 1997;48:81-7.
6. Da Prada M, Borgulya J, Napolitano A, Zurcher G. Improved therapy of Parkinson's disease by tolcapone, a central and peripheral COMT inhibitor with an S-adenosyl-L-methionine sparing effect. Clin Neuropharmacol 1994;17[3 suppl]:S26-S37.
7. Bressa GM. S-adenosyl-L-methionine as an antidepressant: metaanalyses of clinical studies. Acta Neurol Scand Suppl 1994; 154:7-14.
8. Moreau JL, Borgulya J, Jenck F, Martin JR. Tolcapone a potential new antidepressant detected in a novel animal model of depression. Behav Pharmacol 1994;5:344-50.
9. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders - Patient Edition (SCID-I/P, Version 2:0). New York: Biometrics Research Department, New York State Psychiatric Institute, 1995.
10. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
11. Guy W, ed. ECDEU assessment manual for psychopharmacology, revised. Department of Health, Education, and Welfare Publication No. (ADM)76-338. Rockville, MD: National Institute of Mental Health, 1976.
12. Beck AT, Ward CE, Mendelson M. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-71.
13. Lieber CS, Casini A, DeCarli LM, Kim CI, Lowe N, Sasaki R, Leo MA. S-adenosyl-L-methionine attenuates alcohol-induced liver injury in the baboon. Hepatology 1990;11:165-72.
14. Fawcett J, Epstein P, Fiester SJ, Elkin I, Autry JH. Clinical Management-Imipramine/Placebo Administration Manual: NIMH Treatment of Depression Collaborative Research Program. Psychopharmacol Bull 1987;23:309-24.
15. Renshaw PF, Lafer B, Babb SM, Fava M, Stoll AL, Christensen JD, Moore CM, Yurgelun-Todd DA, Bonello CM, Pillay SS, Rothschild AJ, Nierenberg AA, Rosenbaum JF, Cohen BM. Basal ganglia choline levels in depression and response to fluoxetine treatment: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 1997;41:837-43.
16. Barkai AI, Dunner DL, Gross HA, Mayo P, Fieve R. Reduced myoinositol levels in cerebrospinal fluid from patients with affective disorder. Biol Psychiatry 1978;13:65-72.
17. Pelech SL, Vance DE. Signal transduction via phosphatidylcholine cycles. Trends Biochem Sci 1989;14:28-30.
18. Barbaran JL, Worley PF, Snyder SJ. Second messenger systems and psychoactive drug action: focus on the phosphoinositide system and lithium. Am J Psychiatry 1989;146:1251-60.
19. Webb PG, Sailasuta N, Kohler SJ, Raidy T, Moats RA, Hurd RE. Automated single-voxel proton MRS: technical development and multisite verification. Magn Reson Med 1994;31: 365-73.
20. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: Erlbaum, 1988.
21. Singaram C, Ashraf W, Gaumnitz EA, Torbey C, Sengupta A, Pfeiffer R, Quigley EMM. Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation. Lancet 1995;346:861-4.